| Autor: |
Durant, J., Chantre, Ph., Gonzalez, G., Vandermander, J., Halfon, Ph., Rousse, B., Guédon, D., Rahelinirina, V., Chamaret, S., Montagnier, L., Dellamonica, P. |
| Zdroj: |
Phytomedicine; March 1998, Vol. 5 Issue: 1 p1-10, 10p |
| Abstrakt: |
The objective of the present study was to compare the efficacy and safety of two doses of SPV30in HIV asymptomatic patients. The study was designed as a randomized double-blind multicentre trial of two doses of SPV30(990 mg/d and 1980 mg/d) versus placebo. 145 previously untreated subjects with asymptomatic HIV infection (CDC group IV) and CD4 cell counts between 250 and 500 × 106/1 were recruited. There was a statistically significant difference in therapeutic failures between groups in favor of SPV30990 mg including decreases of CD4 cell count < 200 × 106/1 and/or number of clinical aggravations (progression to AIDS or AIDS related complex). The treatment groups differed statistically in the rate of disease progression also in favor of SPV30990 mg/d. Fewer patients receiving SPV30990 mg/d had at the end an increase of viral load greater than 0.5 log (P= 0.029). No severe side-effects were reported in the 3 groups. From these results we conclude that SPV30990 mg/d has beneficial effects in HIV asymptomatic patients and appears to delay the progression of HIV disease. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect